Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab plus IVIG for early regression of coronary artery lesions in Kawasaki disease
ChiCTR2000037634Phase 4Recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab, Human normal immunoglobulin G and aspirin in Kawasaki disease (KD) (2 arms), sponsored by Children's Hospital of Fudan University. Primary endpoint: Percentage of regression of coronary artery lesion at one month of illness. Started Oct 2020; status: recruiting.
02
Drugs
infliximabHuman normal immunoglobulin Gaspirin
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on ChiCTR2000037634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037634.